Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes
Importance In the treatment of type 2 diabetes, evidence of the comparative effectiveness of
sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas—the second most …
sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas—the second most …
Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin
R Fontes-Carvalho, D Santos-Ferreira… - European Journal of …, 2022 - academic.oup.com
The cardiovascular and renal systems are closely interconnected in health and disease.
Disorders affecting one of these systems frequently involve the other. Both diseases …
Disorders affecting one of these systems frequently involve the other. Both diseases …
Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis
Background Kidney benefits have been demonstrated for both sodium-glucose
cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) …
cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) …
[HTML][HTML] Ootheca mantidis mitigates renal fibrosis in mice by the suppression of apoptosis via increasing the gut microbe Akkermansia muciniphila and modulating …
J Wang, X Guo, Z Zou, M Yu, X Li, H Xu, Y Chen… - Biomedicine & …, 2023 - Elsevier
Renal interstitial fibrosis (RIF), a progressive process affecting the kidneys in chronic kidney
disease (CKD), currently lacks an effective therapeutic intervention. Traditional Chinese …
disease (CKD), currently lacks an effective therapeutic intervention. Traditional Chinese …
Adolescent body mass index and early chronic kidney disease in young adulthood
Importance Despite increasing obesity rates in adolescents, data regarding early kidney
sequelae are lacking. Objective To assess the association between adolescent body mass …
sequelae are lacking. Objective To assess the association between adolescent body mass …
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
CP Limonte, YN Hall, S Trikudanathan, KR Tuttle… - Journal of Diabetes and …, 2022 - Elsevier
Aims To determine national prevalence of sodium-glucose contransporter-2 inhibitor
(SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1RA) use among adults with …
(SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1RA) use among adults with …
SGLT2 inhibitors: a narrative review of efficacy and safety
DS Nelinson, JM Sosa, RJ Chilton - Journal of osteopathic medicine, 2021 - degruyter.com
Type 2 diabetes mellitus (T2DM) is a cardio-renal-metabolic condition that is frequently
associated with multiple comorbidities, including atherosclerotic cardiovascular disease …
associated with multiple comorbidities, including atherosclerotic cardiovascular disease …
SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes
DC Wheeler, J James, D Patel, A Viljoen, A Ali… - Diabetes Therapy, 2020 - Springer
Diabetic kidney disease (DKD) is a topic of increasing concern among clinicians involved in
the management of type 2 diabetes mellitus (T2DM). It is a progressive and costly …
the management of type 2 diabetes mellitus (T2DM). It is a progressive and costly …
Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost …
Aims/hypothesis Whether sodium–glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-
like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their …
like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their …
Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial …
P McEwan, H Bennett, K Khunti… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aims The economic burden of diabetes is driven by the management of vascular
complications. Sodium–glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated …
complications. Sodium–glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated …